12. HYPOGLYCEMIC AGENTS

HYPOGLYCEMIC AGENTS: A TEACHER’S COMPREHENSIVE GUIDE

Welcome, future pharmacists and healthcare professionals!

Diabetes mellitus is one of the most common and rapidly growing chronic diseases worldwide, affecting millions of people. Hypoglycemic agents are medications used to lower blood glucose levels in the treatment of diabetes mellitus. With the exceptions of insulin, exenatide, liraglutide, and pramlintide, all other hypoglycemic agents are administered orally and are therefore known as oral hypoglycemic agents or oral anti-hyperglycemic agents.

As a pharmaceutical chemistry educator with years of experience teaching endocrinology and pharmacology, I have observed that students often find this topic challenging due to the variety of drug classes and their complex mechanisms of action. Let me tell you: Understanding hypoglycemic agents is essential for every pharmacy professional.

In this comprehensive guide, I will walk you through the major classes of hypoglycemic agents—sulphonylureas, biguanides, meglitinides, thiazolidinediones, and newer agents like gliflozins and gliptins. I will explain their classifications, mechanisms of action, uses, stability, and formulations. By the end of this article, you will have a thorough understanding of these essential antidiabetic medications. Let us begin our journey!

Dpharmguru’s exam insights:

Hypoglycemic agents are frequently tested in pharmacy exams. Remember: Diabetes Mellitus is a disease of sustained high blood sugar levels. Type 1 diabetes requires insulin, while Type 2 diabetes can be managed with oral hypoglycemic agents. Pay special attention to the mechanisms of action and classifications—these are almost always asked in exams! Also, remember the difference between insulin and oral hypoglycemics—this is a classic exam question.

DIABETES MELLITUS: AN OVERVIEW

Diabetes Mellitus (DM) can be defined as a disease of sustained high blood sugar levels. It can be subclassified into various categories:

• Type 1 Diabetes: Insulin-dependent diabetes; the body does not produce insulin
• Type 2 Diabetes: Non-insulin-dependent diabetes; the body does not use insulin properly
• Maturity-Onset Diabetes of the Young (MODY)
• Gestational Diabetes: Develops during pregnancy
• Neonatal Diabetes
• Steroid-Induced Diabetes

9.1. CLASSIFICATION OF HYPOGLYCEMIC AGENTS

• Sulphonylureas: Carbutamide, Tolbutamide, Chlorpropamide, Acetohexamide, Glibenclamide, Glipizide, Glimepiride
• Biguanides: Phenformin, Metformin, Buformin
• Substituted Benzoic Acid Derivatives (Meglitinides): Meglitinide, Repaglinide, Nateglinide
• Thiazolidinediones (Glitazones): Pioglitazone, Ciglitazone, Rosiglitazone
• Miscellaneous: Linogliride, Palmoxirate sodium
• SGLT-2 Inhibitors (Gliflozins): Canagliflozin, Dapagliflozin, Empagliflozin
• DPP-4 Inhibitors (Gliptins): Sitagliptin, Vildagliptin, Saxagliptin

9.2. EXAMPLES OF HYPOGLYCEMIC AGENTS

9.2.1. Insulin

Paul Langerhans (a German medical student) in 1869 studied that the pancreas has two different groups of cells—the acinar cells that secrete digestive enzymes, and islets (cells clustered in islands) that serve a second function. Banting, Macleod, Best, and Collip isolated insulin from bovine pancreas and used it for treating diabetes mellitus.

Insulin is a hormone produced in the pancreas that permits the body to utilise sugar (glucose) from carbohydrates in the food. Insulin restricts the blood sugar levels from getting too high (hyperglycaemia) or too low (hypoglycaemia).

Physical Properties:

• Occurs as a white or almost white coloured crystalline powder
• Faintly soluble in water
• Soluble in dilute solution of mineral acids (with degradation in solutions of alkali hydroxide)
• Almost insoluble in alcohol, chloroform, and ether

Insulin Preparations and Duration of Action

Biosynthesis of Insulin

Significant quantity of insulin is synthesised in the pancreatic beta cells. The insulin mRNA is translated as a single chain precursor known as pre-pro-insulin, and removal of its signal peptide during insertion into the endoplasmic reticulum produces pro-insulin.

Pro-insulin contains three domains:

• An amino-terminal B chain
• A carboxy-terminal A chain
• A C peptide (connecting peptide in the middle)

Pro-insulin, in the endoplasmic reticulum, is exposed to specific endopeptidases that excise the C peptide and generates the mature form of insulin. Insulin and free C peptide are packaged in the Golgi into secretory granules accumulating in the cytoplasm.

Insulin is secreted from the pancreatic β-cells by exocytosis when these cells are stimulated. After its release, the insulin diffuses into islet capillary blood. C peptide is also secreted into the bloodstream; however, it is not biologically active.

Uses of Insulin

• Controlling diabetes mellitus (uncontrollable by diet alone) or treating insulin-dependent diabetes mellitus
• Regulating carbohydrate metabolism
• Treating hyperkalemia
• Treating severe ketoacidosis or diabetic coma

Stability and Storage Conditions of Insulin

• Insulin (unopened) should be stored in the refrigerator at a temperature between 2°C to 8°C (36°F to 46°F)
• It should not be frozen; if frozen, it should not be used
• Insulin can be stored until the expiration date on the label

Dpharmguru’s exam insights:

Insulin is a frequently tested topic. Remember: Insulin is a peptide hormone produced by pancreatic β-cells. It exists in various formulations—rapid-acting, short-acting, intermediate-acting, and long-acting. The biosynthesis involves pre-pro-insulin → pro-insulin → insulin + C peptide. A common exam question is: “What is the storage temperature for unopened insulin?” (Answer: 2°C to 8°C).

9.2.2. Metformin

Metformin is a biguanide antihyperglycemic agent. It improves glycemic control by decreasing hepatic glucose production and glucose absorption, and also by increasing insulin-mediated glucose uptake.

Chemical Name: N,N-Dimethylimidodicarbonimidic diamide

Mechanism of Action: Metformin reduces blood glucose levels by:

• Decreasing hepatic glucose production (gluconeogenesis)
• Decreasing the intestinal absorption of glucose
• Increasing insulin sensitivity by increasing glucose uptake and utilisation by peripheral tissues

Uses:

• Adjunct to diet and exercise in NIDDM patients older than 18 years
• Managing metabolic and reproductive abnormalities related to polycystic ovary syndrome (PCOS)
• With a sulphonylurea or insulin to improve glycemic control in adults

Stability & Storage: Keep in tightly closed container, out of reach of children. Store at room temperature away from light, excess heat, and moisture. Do not store in the bathroom.

Formulations: Suspension, Tablet, Solution

Brand Names: Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet

9.2.3. Glibenclamide (Glyburide)

Glibenclamide is an oral antihyperglycemic drug of the sulphonylurea class. It is a white to silver crystalline compound with molecular formula C₂₃H₂₈ClN₃O₅S and molecular weight 494.00.

Chemical Name: 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide

Mechanism of Action: Glibenclamide lowers blood glucose levels acutely by stimulating the release of insulin from the pancreas. This effect depends upon functioning β-cells in the pancreatic islets. Extrapancreatic effects may also play a part in its mechanism of action.

Uses:

• Treating patients with impairment of hepatic function
• Acts as a hypoglycemic and hematologic agent

Stability & Storage: Can be stored at a temperature of more than 40°C or at 40°C for at least 90 days.

Formulation: Tablets

Brand Names: Diabeta, Flycron, Glyburide

9.2.4. Glimepiride

Glimepiride is the third-generation sulphonylurea. It is a highly potent sulphonylurea having a long duration of action.

Chemical Name: 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide

Mechanism of Action: Glimepiride decreases blood glucose levels by:

• Stimulating insulin release from functioning pancreatic β-cells
• Increasing the sensitivity of peripheral tissues to insulin
• Binding to ATP-sensitive potassium channels on pancreatic cell surface, depolarising the membrane and reducing potassium conductance
• Stimulating influx of Ca²⁺ ions through voltage-sensitive calcium channels, inducing secretion/exocytosis of insulin

Uses: Used with insulin for treating non-insulin-dependent (type 2) diabetes mellitus.

Stability & Storage: Store at room temperature between 68°F and 77°F (20°C and 25°C). Do not refrigerate.

Formulation: Tablets

Brand Name: Amaryl

Dpharmguru’s exam insights:

Sulphonylureas are frequently tested. Remember: First-generation sulphonylureas include Tolbutamide and Chlorpropamide. Second-generation includes Glibenclamide and Glipizide. Third-generation includes Glimepiride. All sulphonylureas stimulate insulin release from pancreatic β-cells. Glimepiride is the most potent and has the longest duration of action.

9.2.5. Pioglitazone

Pioglitazone is used as an adjunct to diet, exercise, and other anti-diabetic drugs to control type 2 diabetes mellitus. It belongs to the thiazolidinedione (glitazone) class.

Chemical Name: 5-{4-[2-(5-ethyl-2-pyridinyl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione

Mechanism of Action: Pioglitazone is a selective agonist of Peroxisome Proliferator Activated Receptor-γ (PPARγ) present in target tissues (adipose tissue, skeletal muscle, and liver) for insulin action. PPARγ receptors on activation increase the transcription of insulin-responsive genes involved in controlling production, transport, and utilisation of glucose. Thus, pioglitazone enhances tissue sensitivity to insulin and reduces glucose production via hepatic gluconeogenesis.

Uses: Adjunct to diet and exercise for improving glycemic control in individuals with type 2 diabetes mellitus.

Stability & Storage: Store at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F). Container should be tightly closed and protected from light, moisture, and humidity.

Formulation: Tablets

Brand Name: Actos

9.2.6. Repaglinide

Repaglinide is used for treating NIDDM. It is an oral anti-hyperglycemic drug of the meglitinide class having short-acting insulin secretagogues that bind to pancreatic β-cells for stimulating insulin release.

Chemical Name: 2-ethoxy-4-[2-({3-methyl-1-[2-(1-piperidinyl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid

Mechanism of Action: Repaglinide depends on the presence of functioning pancreatic β-cells and glucose. It potentiates the effect of extracellular glucose on ATP-sensitive potassium channels and produces little effect on insulin levels between meals and overnight. It more effectively reduces post-prandial blood glucose levels than fasting blood glucose levels.

Uses: Adjunct to diet and exercise for improving glycemic regulation in individuals with type 2 diabetes mellitus.

Stability & Storage: Store at room temperature between 59-77°F (15-25°C), away from light and moisture. Do not store in bathroom.

Formulations: Tablets, Capsules

Brand Names: Enyglid, Gluconorm, Prandin

9.2.7. Gliflozins (SGLT-2 Inhibitors)

Gliflozin drugs are a newly developed class of oral hypoglycemic agents—the sodium-glucose co-transporter 2 (SGLT-2) inhibitors—used in the treatment of type 2 diabetes mellitus.

Mechanism of Action: SGLT-2 protein gets blocked by this class of drugs from the site of the proximal convoluted tubule (PCT) in the kidney, which results in preventing reabsorption of glucose molecules and allowing excretion of glucose in urine. The blood glucose level in the body gets lowered by this mechanism.

Uses:

• Type 1 diabetes
• Type 2 diabetes

Stability & Storage: Store at room temperature, away from light and moisture.

Formulation: Tablets

Brand Names: Canagliflozin, Dapagliflozin, Empagliflozin

9.2.8. Gliptins (DPP-4 Inhibitors)

Gliptins are DPP-4 inhibitors that are a recently introduced class of oral drugs intended for the treatment of type 2 diabetes. They block the metabolism by the DPP-4 enzyme of incretin hormones, including GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which are secreted by the intestine in response to food.

Mechanism of Action:

• Food is broken down into sugar (glucose) by the digestive system, thus increasing the incretins
• The pancreas releases insulin in response to food
• Active glucagon-like peptide-1 (GLP-1) is secreted by the L cells of the intestines
• In the absence of gliptin, GLP-1 is rapidly inactivated and degraded by the enzyme dipeptidyl peptidase IV (DPP4)
• Gliptin binds to DPP4, allowing GLP-1 to remain active
• Active GLP-1 increases insulin release and decreases glucagon release from the pancreas

Uses: Gliptins are prescribed when proper diet and regular exercise cannot control blood glucose levels in type 2 diabetes.

Stability & Storage: Keep at room temperature between 68°F and 77°F (20°C and 25°C), away from heat, air, and light. Keep out of children’s reach.

Formulation: Tablets

Brand Names:

• Januvia (Sitagliptin)
• Galvus (Vildagliptin)
• Onglyza (Saxagliptin)
• Tradjenta (Linagliptin)

Dpharmguru’s exam insights:

Newer hypoglycemic agents are increasingly tested in exams. Remember: Gliflozins (SGLT-2 inhibitors) work by blocking glucose reabsorption in the kidney, causing glucose excretion in urine. Gliptins (DPP-4 inhibitors) work by preventing the breakdown of incretin hormones, increasing insulin release. A common exam question is: “What is the mechanism of action of gliflozins?” (Answer: SGLT-2 inhibition in the kidney).

COMPARISON: HYPOGLYCEMIC AGENTS

FREQUENTLY ASKED QUESTIONS (FAQs)

1. What is the difference between Type 1 and Type 2 diabetes?

Type 1 diabetes is insulin-dependent; the body does not produce insulin and requires exogenous insulin. Type 2 diabetes is non-insulin-dependent; the body does not use insulin properly (insulin resistance) and can often be managed with oral hypoglycemic agents.

2. What is the mechanism of action of metformin?

Metformin reduces blood glucose levels by decreasing hepatic glucose production (gluconeogenesis), decreasing intestinal absorption of glucose, and increasing insulin sensitivity by increasing glucose uptake and utilisation by peripheral tissues.

3. What is the difference between sulphonylureas and meglitinides?

Both stimulate insulin release from pancreatic β-cells. Sulphonylureas (like Glibenclamide) have a longer duration of action, while meglitinides (like Repaglinide) are short-acting and primarily reduce post-prandial glucose levels.

4. What is the mechanism of action of gliflozins?

Gliflozins are SGLT-2 inhibitors that block glucose reabsorption in the proximal convoluted tubule of the kidney, causing glucose to be excreted in urine and lowering blood glucose levels.

5. What is the mechanism of action of gliptins?

Gliptins are DPP-4 inhibitors that prevent the breakdown of incretin hormones (GLP-1 and GIP), allowing them to remain active longer. This increases insulin release and decreases glucagon release from the pancreas.

6. What is the recommended storage temperature for insulin?

Unopened insulin should be stored in the refrigerator at a temperature between 2°C to 8°C (36°F to 46°F). It should not be frozen.

SUMMARY

Hypoglycemic agents are essential medications for the management of diabetes mellitus. This guide covered the major classes:

• Insulin: The primary treatment for Type 1 diabetes; available in rapid-acting, short-acting, intermediate-acting, and long-acting formulations
• Biguanides (Metformin): First-line oral therapy for Type 2 diabetes; decreases hepatic glucose production and increases insulin sensitivity
• Sulphonylureas (Glibenclamide, Glimepiride): Stimulate insulin release from pancreatic β-cells
• Meglitinides (Repaglinide): Short-acting insulin secretagogues that reduce post-prandial glucose
• Thiazolidinediones (Pioglitazone): PPARγ agonists that increase insulin sensitivity
• SGLT-2 Inhibitors (Gliflozins): Block glucose reabsorption in the kidney
• DPP-4 Inhibitors (Gliptins): Prevent breakdown of incretin hormones

As I always tell my students: “Understanding hypoglycemic agents is essential for managing diabetes mellitus—one of the most common and challenging diseases in clinical practice. Each drug class has a unique mechanism and role in patient care.”

REFERENCES AND FURTHER READING

• Pharmacy Council of India (PCI). (2022). Pharmacology Syllabus. New Delhi: PCI.
• Rang, H. P., & Dale, M. M. (2021). Rang & Dale’s Pharmacology (9th ed.). Elsevier.
• Goodman, L. S., & Gilman, A. (2018). Goodman & Gilman’s The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill.
• Katzung, B. G. (2021). Basic and Clinical Pharmacology (15th ed.). McGraw-Hill.
• Williams, D. A., & Lemke, T. L. (2019). Foye’s Principles of Medicinal Chemistry (8th ed.). Wolters Kluwer.
• American Diabetes Association. (2023). Standards of Medical Care in Diabetes. Diabetes Care.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals for medical concerns. Pharmaceutical regulations and guidelines may vary by region—always refer to your local regulatory authorities for specific requirements.

written by:
Dr. N. Sujith Kumar

Dr. N. Sujith Kumar is a pharmacy educator, Pharm.D graduate, and academic content creator from Jawaharlal Nehru Technological University Kakinada (JNTUK), where he completed his Doctor of Pharmacy (Pharm.D) degree between 2015 and 2021. He has more than 7 years of experience creating pharmacy educational content, writing study materials, and reviewing academic articles for pharmacy students. He has also contributed guest articles to pharmacy education platforms, including PharmD Guru. At D.PharmGuru, his work focuses on simplifying complex Diploma in Pharmacy (D.Pharmacy) subjects into easy-to-understand notes, practical explanations, and exam-oriented educational resources for students across India. His areas of focus include Human Anatomy and Physiology, Pharmaceutics, Pharmacology, Pharmaceutical Chemistry, Hospital and Clinical Pharmacy, and other core D.Pharmacy subjects.

For More Study Materials, Visit: www.dpharmguru.com